Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Monoclonal Gammopathy
NCT03820817Phase 1Completed
- Sponsor
- Emory University
- Start
- May 2019
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifaximin in monoclonal gammopathy of undetermined significance (MGUS), sponsored by Emory University. Primary endpoint: Clinical response rate at 2 weeks. Started May 2019; status: completed.
02
Drugs
rifaximin
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on NCT03820817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820817.